Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319)
NCT07371533
·
clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Acute Lymphocytic Leukemia
Interventions
DRUG:
Treatment with A319
Sponsor
Shanxi Bethune Hospital